JAK inhibitors find their tier
Oral JAK inhibitors are settling into a defined tier across rheumatology, IBD, and dermatology after several years of label and safety recalibration.
After the post-marketing safety updates, oral JAK inhibitors have settled into a recognisable tier in immunology - typically after a biologic, with patient-selection guardrails. The convenience advantage is real but bounded.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
- ExplainedWhat is lupus nephritis?
- SnapshotLupus nephritis therapy reference (2026)
- ExplainedWhat is Sjogren disease?
- ExplainedWhat is ANCA-associated vasculitis?
← Back to Signals
Published by PatientSpotlight, by PanaceaIntel.